Condition · High confidence
HBOT for Long COVID
Post-viral fatigue and cognitive symptoms are converting into consistent self-pay HBOT demand. Randomized data from Israeli centers plus an organized patient advocacy layer is pulling inquiries forward faster than payer policy is moving, which keeps this a cash-pay growth lane for the next 12–18 months.
Momentum
92
30d change
+18%
90d change
+54%
Confidence
High
What's driving it
- Sham-controlled trial data reporting cognitive and fatigue improvement at 40 sessions
- Patient advocacy groups publishing clinic directories and protocol comparisons
- Primary care referral hesitancy easing as peer-reviewed replications accumulate
Risks and counter-signals
- No CMS or major commercial coverage pathway yet — demand is price-elastic
- Heterogeneous Long COVID definitions weaken outcome comparability
- Advertising claims scrutiny is rising in several states
Recommended actions
- Build a dedicated post-viral intake page with outcome expectations and pricing tiers
- Track 40-session completion rate; drop-off above 25% signals a pricing/scheduling problem
- Prepare a physician one-pager summarizing the strongest three trials
Signal panel
- Search interest 90d
- +54%
- New publications 90d
- 17
- Clinics advertising
- +31%
- Payer coverage
- None material